Collectively, these findings indicate that upregulation of miR-665 promotes IBD progression by inactivating ER stress signaling via targeting XBP1 and ORMDL3, and miR-665 might be a potential therapeutic target. Here, ORMDL3 is linked to inflammatory bowel disease.